The mechanism: BWX Technologies has a business most investors never think about, because it's boring by design. It is the sole qualified manufacturer of naval nuclear reactor fuel and reactor components for every U.S. Navy submarine and aircraft carrier — Virginia, Ohio, Seawolf, Los Angeles, Columbia-class boats, plus Nimitz and Ford-class carriers. That's not a contract that competes for renewal; it's a monopoly baked into the Naval Nuclear Propulsion Program, funded through defense appropriations that survive administrations, recessions, and rate cycles. In 2025 alone BWXT booked roughly $2.6 billion in new naval reactor-component awards on top of a steady cadence of fuel contracts (a $174 million Naval Nuclear Fuel award in September, work running through mid-2026). That's the base.
What's changing is the second leg. The same manufacturing base — the machining, the fuel fabrication, the security clearances — is now being deployed against two civilian-adjacent policy pushes: DOE/DoD microreactor development and domestic medical-isotope onshoring. BWXT is the fuel supplier for Project Pele, the Pentagon's transportable microreactor demonstration at Idaho National Laboratory, and in late 2025 delivered the first full TRISO fuel core for that program — a concrete, DOE-tracked milestone, not a promise. Separately, BWXT Medical has inked a multi-year supply agreement with NorthStar Medical Radioisotopes to produce actinium-225, a cancer-therapy isotope Washington has explicitly flagged as a supply-chain priority after decades of import dependence on foreign reactors.